NCT00910299

Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)

Effectiveness of Prasugrel Versus Clopidogrel in Subjects With High Platelet Reactivity on Clopidogrel Following Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stent

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 423 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To determine the efficacy of prasugrel versus clopidogrel for the reduction of adverse cardiovascular outcomes in patients with high platelet reactivity on clopidogrel after successful implantation of coronary drug-eluting stents. To determine the adverse event profile of prasugrel in patients with high platelet reactivity on clopidogrel after implantation of coronary drug-eluting stents. To determine the effect of prasugrel on inhibition of platelet activation in patients with high platelet reactivity on clopidogrel.

Conditions

• Coronary Artery Disease (CAD)

Interventions

Type	Name	Description
DRUG	Prasugrel	One time 60 milligram (mg) oral loading dose and 10 mg once daily oral maintenance dose up to 6 months.
DRUG	Clopidogrel	75 mg oral daily maintenance dose up to 6 months.

Timeline

• Start date: 2009-07-01
• Primary completion: 2011-04-01
• Completion: 2011-04-01
• First posted: 2009-05-29
• Last updated: 2012-06-08
• Results posted: 2012-06-08

Locations

27 sites across 2 countries: United States, Germany